Aclarion Targets 2026 CLARITY Trial Readout with Cash Runway into 2028
Event summary
- Aclarion anticipates initial internal readout of its 300-patient CLARITY trial by Q3 2026, with interim results expected in Q4 2026.
- Company has cash runway extending into 2028, with no plans to raise additional capital before CLARITY trial results.
- ATM terminated in early 2025 and ELOC expired December 31, 2025, reinforcing commitment to shareholder alignment.
- Aclarion has 2,882,371 shares outstanding on a fully diluted basis as of February 2026.
The big picture
Aclarion's 2026 shareholder letter underscores its shift toward a software-native business model, differentiating itself from traditional device companies. The company's focus on biomarker-driven diagnostics for chronic low back pain aligns with broader industry trends toward data-driven, non-invasive solutions. With a clear path to CLARITY trial results and a strengthened balance sheet, Aclarion aims to deliver value to shareholders without additional capital raises, a strategic move that could set a precedent for other MedTech innovators.
What we're watching
- Trial Execution
- How the pace of CLARITY trial enrollment and data collection will impact the timeline for interim results in Q4 2026.
- Financial Discipline
- Whether Aclarion can maintain its no-capital-raise stance through 2028, given the extended cash runway.
- Market Positioning
- The effectiveness of Aclarion's investor-awareness strategy in positioning itself as a software-native MedTech innovator.
Related topics